Hypermethylation of thymosin β4 predicts a poor prognosis for patients with acute-on-chronic hepatitis B liver failure.

Wang H, Yin YP, Wang ZL, Qian Y, Fan YC, Liu HH, Wang K

Hepatobiliary & pancreatic diseases international : HBPD INT19 Aug 2022Cited by 2 (Europe PMC)

PMID36041971DOI10.1016/j.hbpd.2022.08.005PepBankPUB-36041971

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Natural levels measured8

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

01HumanEndogenous levelObservational studyOther
In patients with acute-on-chronic hepatitis B liver failure, Tβ4 promoter methylation status correlated negatively with Tβ4 mRNA levels.
In plain wordsIn people with this liver failure, more methylation of the gene for the body's own Tβ4 was linked to lower Tβ4 mRNA levels.
Peptide
Thymosin beta-4 (human)
Outcome
Not applicableCorrelation of Tβ4 promoter methylation with Tβ4 mRNA
Study
n = 115
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
In patients with ACHBLF, Tβ4 promoter methylation status correlated negatively with mRNA levels.
2 context sentences(design, population, supporting numbers)
Summary · context
The study recruited 115 patients with ACHBLF, 80 with acute-on-chronic hepatitis B pre-liver failure (pre-ACHBLF), and 86 with chronic hepatitis B (CHB).
Summary · context
Tβ4 promoter methylation status in peripheral blood mononuclear cells (PBMCs) was measured by methylation-specific polymerase chain reaction, and mRNA was detected by quantitative real-time polymerase chain reaction.
This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3604197103
02HumanEndogenous levelObservational studyOther
In patients with acute-on-chronic hepatitis B liver failure, 3-month mortality was significantly higher in the methylated group than in the unmethylated group.
In plain wordsIn people with this liver failure, more of those with a methylated gene for the body's own Tβ4 died within 3 months than those without.
Peptide
Thymosin beta-4 (human)
Outcome
Increase3-month mortality by Tβ4 methylation status
Study
n = 115
Outcome group
Mortality · Liver
Source sentences
Summary
The 3-month mortality of ACHBLF in the methylated group was significantly higher than that in the unmethylated group.
2 context sentences(design, population, supporting numbers)
Summary · context
The study recruited 115 patients with ACHBLF, 80 with acute-on-chronic hepatitis B pre-liver failure (pre-ACHBLF), and 86 with chronic hepatitis B (CHB).
Summary · context
Tβ4 promoter methylation status in peripheral blood mononuclear cells (PBMCs) was measured by methylation-specific polymerase chain reaction, and mRNA was detected by quantitative real-time polymerase chain reaction.
This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3604197104
03HumanEndogenous levelObservational studyOther
Methylation frequency of Tβ4 was significantly higher in patients with acute-on-chronic hepatitis B liver failure than in those with pre-liver failure, chronic hepatitis B or healthy controls.
In plain wordsThe gene for the body's own Tβ4 was more often methylated in people with this liver failure than in the other groups.
Peptide
Thymosin beta-4 (human)
Outcome
IncreaseTβ4 methylation frequency in ACHBLF versus pre-ACHBLF, CHB and healthy controls
Study
n: not reported in source
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
Methylation frequency of Tβ4 was significantly higher in patients with ACHBLF than in those with pre-ACHBLF, CHB or HCs.
2 context sentences(design, population, supporting numbers)
Summary · context
The study recruited 115 patients with ACHBLF, 80 with acute-on-chronic hepatitis B pre-liver failure (pre-ACHBLF), and 86 with chronic hepatitis B (CHB).
Summary · context
Tβ4 promoter methylation status in peripheral blood mononuclear cells (PBMCs) was measured by methylation-specific polymerase chain reaction, and mRNA was detected by quantitative real-time polymerase chain reaction.
This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3604197101
04HumanEndogenous levelObservational studyOther
Expression of Tβ4 mRNA showed the opposite trend, so it was lower in patients with acute-on-chronic hepatitis B liver failure than in the other groups.
In plain wordsThe body's own Tβ4 mRNA levels were lower in people with this liver failure than in the other groups.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseTβ4 mRNA expression in ACHBLF versus other groups
Study
n: not reported in source
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
However, expression of Tβ4 mRNA showed the opposite trend.
2 context sentences(design, population, supporting numbers)
Summary · context
The study recruited 115 patients with ACHBLF, 80 with acute-on-chronic hepatitis B pre-liver failure (pre-ACHBLF), and 86 with chronic hepatitis B (CHB).
Summary · context
Tβ4 promoter methylation status in peripheral blood mononuclear cells (PBMCs) was measured by methylation-specific polymerase chain reaction, and mRNA was detected by quantitative real-time polymerase chain reaction.
This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3604197102
05HumanEndogenous levelObservational studyOther
Tβ4 promoter methylation frequency was lower in survivors than in non-survivors.
In plain wordsSurvivors had less methylation of the gene for the body's own Tβ4 than people who died.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseTβ4 promoter methylation frequency in survivors versus non-survivors
Study
n: not reported in source
Outcome group
Mortality · Liver
Source sentences
Summary
Also, Tβ4 promoter methylation frequency was lower in survivors than in non-survivors.
2 context sentences(design, population, supporting numbers)
Summary · context
The study recruited 115 patients with ACHBLF, 80 with acute-on-chronic hepatitis B pre-liver failure (pre-ACHBLF), and 86 with chronic hepatitis B (CHB).
Summary · context
Tβ4 promoter methylation status in peripheral blood mononuclear cells (PBMCs) was measured by methylation-specific polymerase chain reaction, and mRNA was detected by quantitative real-time polymerase chain reaction.
This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3604197105
06HumanEndogenous levelObservational studyOther
For predicting the 1-, 2- and 3-month incidence of acute-on-chronic hepatitis B liver failure, Tβ4 methylation status was better than the MELD score.
In plain wordsMethylation of the gene for the body's own Tβ4 predicted who would develop this liver failure better than the MELD score did.
Peptide
Thymosin beta-4 (human)
Outcome
Not applicablePrediction of ACHBLF incidence by Tβ4 methylation versus MELD score
Study
n: not reported in source
Comparator
MELD score
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
When used to predict the 1-, 2-, and 3-month incidence of ACHBLF, Tβ4 methylation status was better than the model for end-stage liver disease (MELD) score.
2 context sentences(design, population, supporting numbers)
Summary · context
The study recruited 115 patients with ACHBLF, 80 with acute-on-chronic hepatitis B pre-liver failure (pre-ACHBLF), and 86 with chronic hepatitis B (CHB).
Summary · context
Tβ4 promoter methylation status in peripheral blood mononuclear cells (PBMCs) was measured by methylation-specific polymerase chain reaction, and mRNA was detected by quantitative real-time polymerase chain reaction.
This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3604197106
07HumanEndogenous levelObservational studyOther
In early-stage and mid-stage liver failure, the predictive value of Tβ4 methylation for mortality was higher than that of the MELD score.
In plain wordsIn early and mid-stage liver failure, methylation of the gene for the body's own Tβ4 predicted death better than the MELD score.
Peptide
Thymosin beta-4 (human)
Outcome
Not applicablePrediction of mortality in early and mid-stage ACHBLF by Tβ4 methylation versus MELD score
Study
n: not reported in source
Comparator
MELD score
Outcome group
Mortality · Liver
Source sentences
Summary
The predictive value of Tβ4 methylation was higher than that of MELD score for the mortality of patients with E-ACHBLF and M-ACHBLF, but not for A-ACHBLF.
2 context sentences(design, population, supporting numbers)
Summary · context
The study recruited 115 patients with ACHBLF, 80 with acute-on-chronic hepatitis B pre-liver failure (pre-ACHBLF), and 86 with chronic hepatitis B (CHB).
Summary · context
Tβ4 promoter methylation status in peripheral blood mononuclear cells (PBMCs) was measured by methylation-specific polymerase chain reaction, and mRNA was detected by quantitative real-time polymerase chain reaction.
This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3604197107
08HumanEndogenous levelObservational studyOther
In advanced-stage liver failure, the predictive value of Tβ4 methylation for mortality was not higher than that of the MELD score.
In plain wordsIn advanced liver failure, methylation of the gene for the body's own Tβ4 did not predict death better than the MELD score.
Peptide
Thymosin beta-4 (human)
Outcome
No significant changePrediction of mortality in advanced-stage ACHBLF by Tβ4 methylation versus MELD score
Study
n: not reported in source
Comparator
MELD score
Outcome group
Mortality · Liver
Source sentences
Summary
The predictive value of Tβ4 methylation was higher than that of MELD score for the mortality of patients with E-ACHBLF and M-ACHBLF, but not for A-ACHBLF.
2 context sentences(design, population, supporting numbers)
Summary · context
The study recruited 115 patients with ACHBLF, 80 with acute-on-chronic hepatitis B pre-liver failure (pre-ACHBLF), and 86 with chronic hepatitis B (CHB).
Summary · context
Tβ4 promoter methylation status in peripheral blood mononuclear cells (PBMCs) was measured by methylation-specific polymerase chain reaction, and mRNA was detected by quantitative real-time polymerase chain reaction.
This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3604197108

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 01:52 UTC
Study results updated
Version 1
12 Oct 2026, 18:17 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.